R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
The company also plans to register the similar range of products in the neighbouring countries.
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Subscribe To Our Newsletter & Stay Updated
